Clinical trial · Interventional
Active Cycle of Breathing Techniques on Respiratory Distress Symptom Cluster
Investigation of the Effect of Active Cycle of Breathing Techniques on Respiratory Distress Symptom Cluster in Patients With Lung Cancer
NCT05879354CI-TRIAL-00091312completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed as a randomized, control group, experimental study to examine the effect of Active Cycle of Breathing Techniques application on respiratory distress symptom cluster in patients with lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Active Cycle of Breathing Techniques | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Active Cycle Of Breathing Techniques Group
- description
- Patients in the intervention group will be provided with video-guided Active Cycle of Breathing Techniques twice a day for 28 days.
- interventionNames
- Other: Active Cycle of Breathing Techniques
- type
- NO_INTERVENTION
- label
- Control group
- description
- No intervention will be given to the patients in the control group.
Primary outcomes (3)
- measure
- Dyspnea Level
- timeFrame
- 28 Days
- description
- The level of dyspnea will be lower in patients in the intervention (experimental) group to whom Active Breathing Cycle techniques were applied, compared to the patients in the control group who did not. The Turkish version of the Cancer Dyspnea Scale, the Turkish Validity and Reliability of which was made by Bitek and Tokem in 2021, will be used to measure the level of dyspnea.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Being 18 years or older * Being diagnosed with stage IV non-small cell lung cancer * Being diagnosed with lung cancer in the type of adenocarcinoma and squamous cell carcinoma * Receiving outpatient chemotherapy treatment * Receiving the first course of chemotherapy treatment * ECOG Performance Scale Score \< 3 * Having all the symptoms of dyspnea, cough, and fatigue * Not having a cognitive disorder or a diagnosed psychiatric illness * Being able to speak Turkish * Volunteering to participate in the research Exclusion Criteria: * Experiencing a chronic obstructive pulmonary disease (COPD) exacerbation in the last 4 weeks * Having an active lung infection * Not volunteering to participate in the research * Not having dyspnea, cough, and fatigue symptoms * Not speaking Turkish
References
Publications (0)
Data not yet available
No reference posted for this study.